Immuron (NASDAQ:IMRN) has been assigned a $15.00 price target by analysts at HC Wainwright in a note issued to investors on Monday, November 20th. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 195.86% from the stock’s current price.
Shares of Immuron (IMRN) traded up $0.20 during midday trading on Monday, hitting $5.07. 3,816 shares of the stock were exchanged, compared to its average volume of 16,773. Immuron has a 12-month low of $4.47 and a 12-month high of $16.34.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2017/12/07/immuron-ltd-imrn-pt-set-at-15-00-by-hc-wainwright-updated-updated.html.
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.
Receive News & Ratings for Immuron Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Ltd and related companies with MarketBeat.com's FREE daily email newsletter.